flâneur

Loss and revival of androgen receptor signaling in advanced prostate cancer | Oncogene

nature.com · 8,529 words · saved by 1 readers

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement Oncogene volume  40,  pages 1205–1216 (2021)Cite this article 13k Accesses 54 Citations 8 Altmetric Metrics details Targeting the androgen receptor (AR) signaling axis has been, over decades, the mainstay of prostate cancer therapy. More potent inhibitors of androgen synthesis and antiandrogens have emerged and have been successfully implemented in clinical practice. That said, the stronger inhibition of the AR signaling axis has led in recent years to an increase of prostate cancers that de-differentiate into AR-negative disease. Unfortunately, this process is intimately linked with a poor prognosis. Here,

Review Article Open access Published: 08 January 2021 Nicolò Formaggio1, Mark A. Rubin ORCID: orcid.org/0000-0002-8321-99502 & Jean-Philippe Theurillat ORCID: orcid.org/0000-0003-0111-59371 Oncogene volume 40, pages 1205–1216 (2021) Cite this article 26k Accesses 143 Citations 7 Altmetric Metrics details Abstract Targeting the androgen receptor (AR) signaling axis has been, over decades, the mainstay of prostate cancer therapy. More potent inhibitors of androgen synthesis and antiandrogens have emerged and have been successfully implemented in clinical practice. That said, the…

saved by

related reading